Basic and clinical immunology – 3011. Evaluation of selected parameters of cellular immunity at diagnosis in children with osteosarcoma

Markiewicz, K; Zeman, Krzysztof; Kozar, Agata; Wawrzyniak, M; Woźniak, Wojciech

doi:10.1186/1939-4551-6-s1-p187

Cited by 11 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Contrary to human OS patients, we found no significant difference in circulating NK cells in canine OS compared to healthy canines (53). It will be of future interest to determine if these primary NK cells are functionally impaired, which would be facilitating tumor growth and has been found in several human cancers (54, 55).…”

Section: Discussioncontrasting

confidence: 95%

NCR1 Expression Identifies Canine Natural Killer Cell Subsets with Phenotypic Similarity to Human Natural Killer Cells

et al. 2016

View full text Add to dashboard Cite

Canines spontaneously develop many cancers similar to humans – including osteosarcoma, leukemia, and lymphoma – offering the opportunity to study immune therapies in a genetically heterogeneous and immunocompetent environment. However, a lack of antibodies recognizing canine NK cell markers has resulted in suboptimal characterization and unknown purity of NK cell products, hindering the development of canine models of NK cell adoptive immunotherapy. To this end, we generated a novel antibody to canine NCR1 (NKp46), the putative species-wide marker of NK cells, enabling purification of NK cells for further characterization. We demonstrate that CD3−/NKp46+ cells in healthy and osteosarcoma-bearing canines have phenotypic similarity to human CD3−/NKp46+ NK cells, expressing mRNA for CD16 and the natural cytotoxicity receptors NKp30, NKp44, and NKp80. Functionally, we demonstrate with the calcein release assay that canine CD3−/NKp46+ cells kill canine tumor cell lines without prior sensitization and secrete IFN-γ, TNF-α, IL-8, IL-10, and granulocyte-macrophage colony-stimulating factor as measured by Luminex. Similar to human NK cells, CD3−/NKp46+ cells expand rapidly on feeder cells expressing 4-1BBL and membrane-bound IL-21 (median = 20,283-fold in 21 days). Furthermore, we identify a minor Null population (CD3−/CD21−/CD14−/NKp46−) with reduced cytotoxicity against osteosarcoma cells, but similar cytokine secretion as CD3−/NKp46+ cells. Null cells in canines and humans have reduced expression of NKG2D, NKp44, and CD16 compared to NKp46+ NK cells and can be induced to express NKp46 with further expansion on feeder cells. In conclusion, we have identified and characterized canine NK cells, including an NKp46− subset of canine and human NK cells, using a novel anti-canine NKp46 antibody, and report robust ex vivo expansion of canine NK cells sufficient for adoptive immunotherapy.

show abstract

Section: Discussioncontrasting

confidence: 95%

NCR1 Expression Identifies Canine Natural Killer Cell Subsets with Phenotypic Similarity to Human Natural Killer Cells

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Clinical data showed that NK cells may play an important role in OS prevention and treatment response. In patients with OS, a lower number of circulating NK cells was observed in peripheral blood compared to normal controls suggesting that NK cells play a preventive role in OS tumor development [23]. Furthermore, patients undergoing treatment for OS demonstrate better survival outcome with faster absolute lymphocyte recovery compared to patient with slow lymphocyte recovery denoting the antitumor role of the immune system in treatment response [24].…”

Section: Discussionmentioning

confidence: 99%

Activated and expanded natural killer cells target osteosarcoma tumor initiating cells in an NKG2D–NKG2DL dependent manner

et al. 2015

View full text Add to dashboard Cite

“…A decrease in NK cell cytotoxicity in older adults is associated with an increased risk of cancer development [ 51 ]. Further, pediatric osteosarcoma (OS) patients have a decreased number of circulating NKs, together implicating NK cells′ potential role in controlling tumor initiation and progression [ 52 ]. Sarcomas have a scarce immune infiltration compared to other solid tumors [ 53 ].…”

Section: Nk Cell Immune Surveillance During Distinct Phases Of Sarmentioning

confidence: 99%

Prospects for NK Cell Therapy of Sarcoma

Lachota

Vincenti

Winiarska

et al. 2020

Cancers

View full text Add to dashboard Cite

Natural killer (NK) cells are innate lymphoid cells with potent antitumor activity. One of the most NK cell cytotoxicity-sensitive tumor types is sarcoma, an aggressive mesenchyme-derived neoplasm. While a combination of radical surgery and radio- and chemotherapy can successfully control local disease, patients with advanced sarcomas remain refractory to current treatment regimens, calling for novel therapeutic strategies. There is accumulating evidence for NK cell-mediated immunosurveillance of sarcoma cells during all stages of the disease, highlighting the potential of using NK cells as a therapeutic tool. However, sarcomas display multiple immunoevasion mechanisms that can suppress NK cell function leading to an uncontrolled tumor outgrowth. Here, we review the current evidence for NK cells’ role in immune surveillance of sarcoma during disease initiation, promotion, progression, and metastasis, as well as the molecular mechanisms behind sarcoma-mediated NK cell suppression. Further, we apply this basic understanding of NK–sarcoma crosstalk in order to identify and summarize the most promising candidates for NK cell-based sarcoma immunotherapy.

show abstract

Basic and clinical immunology – 3011. Evaluation of selected parameters of cellular immunity at diagnosis in children with osteosarcoma

Cited by 11 publications

References 0 publications

NCR1 Expression Identifies Canine Natural Killer Cell Subsets with Phenotypic Similarity to Human Natural Killer Cells

NCR1 Expression Identifies Canine Natural Killer Cell Subsets with Phenotypic Similarity to Human Natural Killer Cells

Activated and expanded natural killer cells target osteosarcoma tumor initiating cells in an NKG2D–NKG2DL dependent manner

Prospects for NK Cell Therapy of Sarcoma

Contact Info

Product

Resources

About